Drug Trial Radar · NCT07513454
A Phase 2 Study of HW211026
Last checked: Nov 20, 2026Latest source record: Jul 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
80
Planned (sponsor's estimate)
Start
Jul 2026
Primary completion
Dec 2026
Study completion Dec 2027
Sponsor
- Lead sponsor
- Hubei Bio-Pharmaceutical Industrial Technological Institute Inc.Industry
- Sponsor type
- Industry
- First posted
- Apr 7, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicenter, randomized, open-label, parallel-group, Phase II clinical trial designed to evaluate the efficacy and safety of HW211026 in adult patients with actinic keratosis.
Conditions
- Actinic Keratosis
Interventions
HW211026Drug
HW211026 ointment dose 1,applied topically on face once daily.
HW211026Drug
HW211026 ointment dose 2,applied topically on face once daily.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Complete Clearance RateTime frame: Day 56
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Shanghai Skin Disease Hospital
Shanghai, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.